Core Viewpoint - Green Leaf Pharmaceutical has signed a collaboration agreement with Jiangsu Enhua Pharmaceutical, granting Enhua exclusive commercialization rights for three long-acting injectable antipsychotic products in mainland China, aimed at enhancing treatment options for schizophrenia patients [1][2]. Group 1: Collaboration Agreement - The agreement includes three products: Rykotan (injectable risperidone microspheres), Rybale (paliperidone palmitate injection), and Meibiri (paliperidone palmitate injection), all intended for the treatment of schizophrenia [1]. - Enhua will be responsible for the exclusive distribution and commercialization of these products in mainland China, while Green Leaf retains ownership of the assets, registration certificates, and all intellectual property rights [1]. - Enhua will pay a non-refundable licensing fee of $20 million to Green Leaf upon signing the agreement, which has a duration of ten years [1]. Group 2: Market Context and Product Development - Schizophrenia is a chronic and highly recurrent disease, with approximately 8 million patients in China, making treatment adherence a significant challenge [2]. - Long-acting injectable antipsychotics, such as those developed by Green Leaf, significantly improve patient compliance compared to oral formulations, serving as an important strategy to prevent relapse [2]. - Rykotan is noted as China's first independently developed long-acting injectable second-generation antipsychotic, while Rybale is the world's first and only paliperidone long-acting injection with a "one injection in the first month" dosing regimen [2]. Group 3: Strategic Importance - The board believes that the three long-acting injectables create a differentiated product portfolio that addresses the treatment needs of schizophrenia patients across all stages of the disease [3]. - The CNS (central nervous system) sector is a core strategic area for Green Leaf, which possesses a competitive product matrix and platform capabilities in this field [3]. - The collaboration with Enhua aims to deepen the market presence in the CNS sector, particularly enhancing product coverage in primary healthcare centers to help more patients receive standardized treatment and reduce the burden of the disease [3].

本文源自：金融界AI电报 绿叶制药(02186.HK)发布公告，集团的若干附属公司与江苏恩华药业股份有限公司的附属公司江苏恩华 和信医药营销有限公司(恩华)签署合作协议，授予恩华三款抗精神病药长效针剂产品在中国大陆地区的 独家商业化权利。该三款产品分别为瑞可妥(注射用利培酮微球(Ⅱ))、瑞百莱(棕榈酸帕利哌酮注射液 (Ⅱ))和美比瑞(棕榈酸帕利哌酮注射液)，均适用于精神分裂症的治疗。 ...

Group 1 - Green Leaf Pharmaceutical has signed a cooperation agreement with Jiangsu Enhua Pharmaceutical, granting Enhua exclusive commercialization rights for three long-acting injectable antipsychotic products in mainland China [1] - The three products include Risperidone microspheres (Riketu), Paliperidone palmitate injection (Ruibailai), and Paliperidone palmitate injection (Meibiri), all aimed at treating schizophrenia [1][2] - Enhua will pay a non-refundable licensing fee of $20 million to Green Leaf Pharmaceutical as part of the agreement, which lasts for ten years [1] Group 2 - Schizophrenia is a chronic, high-recurrence, and highly disabling disease, with approximately 8 million patients in China [2] - Long-acting injectable antipsychotics significantly improve patient compliance compared to oral formulations, making them an important treatment strategy for preventing relapse [2] - The products are developed based on Green Leaf's long-acting and sustained-release technology platform, with Riketu being the first domestically developed second-generation long-acting injectable antipsychotic in China [2] Group 3 - The board believes that the three long-acting injectables form a differentiated product portfolio that addresses the treatment needs of schizophrenia patients at all stages of the disease [3] - CNS (Central Nervous System) is a core strategic area for the company, which aims to accelerate the realization of product pipeline value through strategic partnerships [3] - The collaboration with Enhua will enhance the coverage of these products in primary healthcare centers, helping more patients receive standardized treatment and reduce the burden of the disease [3]

Core Viewpoint - Green Leaf Pharmaceutical (02186.HK) has signed a cooperation agreement with Jiangsu Enhua Pharmaceutical Co., Ltd. and its subsidiary, Jiangsu Enhua Xinyi Pharmaceutical Marketing Co., Ltd., granting Enhua exclusive commercialization rights for three long-acting injectable antipsychotic products in mainland China [1] Group 1: Agreement Details - The three products involved are Risperidone microspheres (Rykotuo), Paliperidone palmitate injection (Ruibailai), and Paliperidone palmitate injection (Meibiri), all indicated for the treatment of schizophrenia [1] - Enhua will be responsible for the exclusive distribution and commercialization of these products in mainland China, while the group retains ownership of the assets, registration certificates, and all intellectual property rights, as well as responsibility for production and supply [1] - The agreement is set for a duration of ten years, with Enhua making a one-time non-refundable payment of $20 million as a licensing fee to the group [1] Group 2: Strategic Implications - This collaboration represents a strong partnership between two leading companies in the central nervous system (CNS) field, aiming to deepen the market presence in schizophrenia treatment and provide more comprehensive treatment options for patients [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 的全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責 任。 LUYE PHARMA GROUP LTD. 綠葉製藥集團有限公司 （於 百 慕 達 註 冊 成 立 之 有 限 公 司） （股 份 代 號：02186） 自願性公告 授予恩華三款抗精神病藥長效針劑產品 於中國大陸的獨家商業化權利 綠葉製藥集團 有限公司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」），董 事 會（「董 事 會」）宣 佈，本 集 團 的 若 干 附 屬 公 司 與 江 蘇 恩 華 藥 業 股 份 有 限 公 司 的 附 屬 公 司 江蘇恩華和信醫藥營銷有限公司（「恩 華」）簽 署 合 作 協 議，授 予 恩 華 三 款 抗 精 神 病 藥 長 效 針 劑 產 品 在 中 國 大 陸 地 區 的 獨 家 商 業 化 權 利。該 三 款 產 品 分 別 為 瑞 可 妥（注 射 用 利 培 酮 微 球（Ⅱ））、瑞 百 萊（ ...

Core Viewpoint - Luye Pharma Group Limited has completed the issuance of 1.5 million exchangeable preferred shares, which can be exchanged for existing shares of Boan Biotechnology, representing approximately 16.15% of Boan's total issued shares [1] Group 1 - The issuer, Luye Geneora Holding Limited, a wholly-owned subsidiary of the company, has allocated and issued 1.5 million exchangeable preferred shares to the subscribers [1] - The exchangeable preferred shares can be converted into shares of Boan Biotechnology without the issuance of any new shares by Boan [1] - Based on the initial exchange price of HKD 11.718, the total number of Boan shares deliverable upon the exchange of all preferred shares is up to 100,486,431 shares [1]

Core Viewpoint - Luye Pharma Group has completed the issuance of 1.5 million exchangeable preferred shares, which can be exchanged for existing shares of Boan Biologics, representing approximately 16.15% of Boan Biologics' total issued shares [1] Group 1 - The issuance of exchangeable preferred shares was finalized on December 12, 2025, according to the terms of the subscription agreement [1] - The issuer, Luye Geneora Holding Limited, a wholly-owned subsidiary of Luye Pharma, allocated and issued the 1.5 million exchangeable preferred shares to the subscribers [1] - The initial exchange price is set at HKD 11.718, allowing for a maximum delivery of 100,486,431 shares of Boan Biologics upon the exchange of all preferred shares [1]

Core Viewpoint - Luye Pharma Group has completed the issuance of 1.5 million exchangeable preferred shares to Bluebell Asset Holding Ltd. as per the terms of the subscription agreement, effective December 12, 2025 [1] Group 1 - The issuer, Luye Geneora Holding Limited, is a wholly-owned subsidiary of Luye Pharma Group [1] - The transaction involves the issuance of exchangeable preferred shares, indicating a strategic move to raise capital [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 之全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何 責 任。 LUYE PHARMA GROUP LTD. 綠葉製藥集團有限公司 （於 百 慕 達 註 冊 成 立 之 有 限 公 司） （股 份 代 號：02186） 須予披露交易 本公司全資附屬公司完成發行可交換優先股 發行可交換優先股 於2025年12月12日，根 據 認 購 協 議 之 條 款，可 交 換 優 先 股 之 發 行 已 完 成。據 此，發 行 人（本 公 司 之 全 資 附 屬 公 司）已向認購人配發及發行1,500,000股可交 換 優 先 股。 該等可交換優先股可交換為本集團所持博安生物之現有股份，並不涉及博安 生 物 發 行 任 何 新 股 份。按 初 始 交 換 價11.718港 元 計 算，於 交 換 所 有 可 交 換 優 先股後可交付的博安生物股份總數最高為100,486,431股，截 至 本 公 告 日 期， 佔博安生物 ...

Core Viewpoint - The announcement of the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog, along with the first edition of the Commercial Health Insurance Innovative Drug Catalog, highlights the inclusion of several new drugs from various pharmaceutical companies, indicating potential growth opportunities in the healthcare sector [1][5]. Group 1: New Drug Inclusions - Green Leaf Pharmaceutical has five new products included in the 2025 National Medical Insurance Drug Catalog or the Commercial Health Insurance Innovative Drug Catalog, including MiMeiXin and RuiBaiLai, marking significant advancements in pain management and treatment options [2][6]. - RoXin Pharmaceutical's core innovative drug, TaiXinZan, has been included in the 2025 National Medical Insurance Drug Catalog, achieving full coverage for its approved indications [6][7]. - Dongcheng Pharmaceutical's product, Technetium-99m labeled Tetrakis, has been successfully included in the National Medical Insurance Drug Catalog, filling a gap in the market for myocardial perfusion imaging agents [8][9]. Group 2: Stock Performance - As of December 8, Green Leaf Pharmaceutical's stock price reached 3.05 yuan, reflecting a 40.55% increase since the beginning of the year [2][6]. - RoXin Pharmaceutical's stock price was 5.18 yuan as of December 9, showing a 35.6% increase year-to-date [7][8]. - Dongcheng Pharmaceutical's stock price was 14.66 yuan as of December 9, with a year-to-date increase of 20.26% [8][9]. - Rongchang Bio's stock price reached 85.29 yuan as of December 9, marking a significant increase of 183.25% since the start of the year [9]. Group 3: Innovative Treatments - MiMeiXin is noted as the first oral naloxone formulation in China for pain management, while RuiBaiLai offers a unique long-acting injection regimen [2][6]. - TaiXinZan has demonstrated superior efficacy in eradicating Helicobacter pylori compared to traditional treatments, showcasing its innovative therapeutic mechanism [7]. - HaiPuYi, a product from LuNan Pharmaceutical, has been included in the first edition of the Commercial Health Insurance Innovative Drug Catalog, addressing a critical shortage in the treatment of phenylketonuria [9].